138 related articles for article (PubMed ID: 14981207)
1. Patient page. Multiple sclerosis treatment: some safety issues to keep in mind.
Aguilar M
Neurology; 2004 Feb; 62(4):E8-9. PubMed ID: 14981207
[No Abstract] [Full Text] [Related]
2. Interrupted therapy: stopping and switching of the beta-interferons prescribed for MS.
Tremlett HL; Oger J
Neurology; 2003 Aug; 61(4):551-4. PubMed ID: 12939437
[TBL] [Abstract][Full Text] [Related]
3. Liver injury associated with the beta-interferons for MS: a comparison between the three products.
Tremlett HL; Yoshida EM; Oger J
Neurology; 2004 Feb; 62(4):628-31. PubMed ID: 14981183
[TBL] [Abstract][Full Text] [Related]
4. Liver injury associated with the beta-interferons for MS.
Francis GS; Kaplowitz N; Alteri E
Neurology; 2004 Sep; 63(6):1142-3; author reply 1142-3. PubMed ID: 15457586
[No Abstract] [Full Text] [Related]
5. Onset of myasthenia gravis in a patient with multiple sclerosis during interferon-1b treatment.
Blake G; Murphy S
Neurology; 1997 Dec; 49(6):1747-8. PubMed ID: 9409387
[No Abstract] [Full Text] [Related]
6. Hepatic reactions during treatment of multiple sclerosis with interferon-beta-1a: incidence and clinical significance.
Francis GS; Grumser Y; Alteri E; Micaleff A; O'Brien F; Alsop J; Stam Moraga M; Kaplowitz N
Drug Saf; 2003; 26(11):815-27. PubMed ID: 12908850
[TBL] [Abstract][Full Text] [Related]
7. Key issues in the diagnosis and treatment of multiple sclerosis. An overview.
O'Connor P;
Neurology; 2002 Sep; 59(6 Suppl 3):S1-33. PubMed ID: 12448786
[No Abstract] [Full Text] [Related]
8. Severe acute hepatitis after resumption of interferon-Beta therapy for multiple sclerosis: a word of caution.
Grieco A; Montalto M; Vero V; Maria Vecchio F; Gasbarrini G
Am J Gastroenterol; 2007 Nov; 102(11):2606-7. PubMed ID: 17958769
[No Abstract] [Full Text] [Related]
9. Autoantibodies in multiple sclerosis patients before and during IFN-beta 1b treatment: are they correlated with the occurrence of autoimmune diseases?
Verdun E; Isoardo G; Oggero A; Ferrero B; Ghezzi A; Montanari E; Zaffaroni M; Durelli L;
J Interferon Cytokine Res; 2002 Feb; 22(2):245-55. PubMed ID: 11911808
[TBL] [Abstract][Full Text] [Related]
10. Interferon-beta treatment decreases cholesterol plasma levels in multiple sclerosis patients.
Morra VB; Coppola G; Orefice G; De Michele G; Vacca G; Filla A; Bonavita V
Neurology; 2004 Mar; 62(5):829-30. PubMed ID: 15007146
[No Abstract] [Full Text] [Related]
11. [Logistics and description of treatment technology (the protocol for using disease modifying drugs--DMD)].
Federal service on surveillance in healthcare and social development (Roszdravnadzor)
Zh Nevrol Psikhiatr Im S S Korsakova; 2011; 111(2 Pt 2):93-8. PubMed ID: 21916163
[No Abstract] [Full Text] [Related]
12. Interferon treatment for multiple sclerosis patients in Hong Kong.
Lau KK; Lee PO; Chan KY; Chan YW; Chin KF
Hong Kong Med J; 2000 Jun; 6(2):221-3. PubMed ID: 10895148
[TBL] [Abstract][Full Text] [Related]
13. Lethal capillary leak syndrome after a single administration of interferon beta-1b.
Niederwieser G
Neurology; 2000 Apr; 54(7):1545-6. PubMed ID: 10751284
[No Abstract] [Full Text] [Related]
14. Autoimmune events during interferon beta-1b treatment for multiple sclerosis.
Durelli L; Ferrero B; Oggero A; Verdun E; Bongioanni MR; Gentile E; Isoardo GL; Ricci A; Rota E; Bergamasco B; Durazzo M; Saracco G; Biava MA; Brossa PC; Giorda L; Pagni R; Aimo G
J Neurol Sci; 1999 Jan; 162(1):74-83. PubMed ID: 10064173
[TBL] [Abstract][Full Text] [Related]
15. Interferon beta-1b for the treatment of multiple sclerosis.
Petri T; Weber-Diehl F
J Biotechnol; 1995 Nov; 43(1):74-5. PubMed ID: 8573325
[No Abstract] [Full Text] [Related]
16. High-dose frequency beta-interferons increase the risk of liver test abnormalities in multiple sclerosis: a longitudinal study.
Chan S; Kingwell E; Oger J; Yoshida E; Tremlett H
Mult Scler; 2011 Mar; 17(3):361-7. PubMed ID: 21148660
[TBL] [Abstract][Full Text] [Related]
17. Interferon beta-1b.
Rudge P
Lancet; 1994 Nov; 344(8935):1511. PubMed ID: 7968150
[No Abstract] [Full Text] [Related]
18. Interferon beta-1b.
Goodkin DE
Lancet; 1994 Oct; 344(8929):1057-60. PubMed ID: 7934448
[No Abstract] [Full Text] [Related]
19. Enhanced spasticity in primary progressive MS patients treated with interferon beta-1b.
Frese A; Bethke F; Lüdemann P; Stögbauer F
Neurology; 1999 Nov; 53(8):1892-3. PubMed ID: 10563657
[No Abstract] [Full Text] [Related]
20. Severe liver dysfunction possibly caused by the combination of interferon beta-1b therapy and melilot (sweet clover) supplement.
Tamura S; Warabi Y; Matsubara S
J Clin Pharm Ther; 2012 Dec; 37(6):724-5. PubMed ID: 22642738
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
